Results 51 to 60 of about 5,941 (192)
Pharma-Clinics Medication of the Month. Rabeprazole (Pariet) [PDF]
, 2002 peer reviewedProton pomp inhibitors (PPI) have revolutionized the treatment of gastro-oesophageal reflux disease and gastro-duodenal ulcers. Rabeprazole (Pariet) is the last PPI arrived on the Belgian market.
Louis, Edouard
core +1 more source
Features of GERD therapy in obese patients: A review
Consilium Medicum, 2023 Epidemiological, endoscopic and pathophysiological studies confirm the relationship between obesity and gastroesophageal reflux disease (GERD) and is characterized by a more severe course, has clinical and pathophysiological features. In the treatment of
Natalia V. Bakulina +3 more
doaj +1 more source
CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 412-419, August 2026.CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park +2 more
wiley +1 more source
Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium
, 2019 The chemical stability of a proton-pump inhibitor, rabeprazole sodium, was evaluated in simulated intestinal fluid (pH 6.8) containing various 'Generally Recognized As Safe (GRAS)'-listed excipients, including Brij® 58 ...
사홍기
core +1 more source
, 2023 Trypanosoma cruzi is the causative agent of American trypanosomiasis, which mainly affects populations in Latin America. Benznidazole is used to control the disease, with severe effects in patients receiving this chemotherapy.
Roberto Hernández (14667827) +9 more
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao +8 more
wiley +1 more source
Mass balance study of [14C] rabeprazole following oral administration in healthy subjects
, 2006 The study was designed to determine the excretion balance of radiolabeled rabeprazole in urine and feces and to examine the metabolite profile in plasma, urine and feces after a single oral dose of [14C] rabeprazole, preceded by once daily dose of ...
Humphries, T J +9 more
core +2 more sources
JGH Open, Volume 10, Issue 8, August 2026.ABSTRACT Aim Tegoprazan, a potassium‐competitive acid blocker, is an acid‐suppressing medication under review as a potential alternative treatment in cases of erosive esophagitis. This systematic review and meta‐analysis assesses the efficacy and tolerability of tegoprazan compared to proton pump inhibitors, the current standard of care. Methods Pubmed,
Youssef Diab +6 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.Machine Learning Enables Rapid Prediction of Acid‐Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling. ABSTRACT pH‐dependent drug–drug interactions (DDIs) commonly occur when acid‐reducing agents (ARAs) are co‐administered with weakly basic drugs.
Yuanfang Qin +6 more
wiley +1 more source
Effective Combination Therapy with Nizatidine and Acotiamide for Functional Dyspepsia
The Indonesian Journal of Gastroenterology, Hepatology and Digestive EndoscopyBackground: The two subgroups of Functional Dyspepsia (FD), including Postprandial Distress Syndrome (PDS) and Epigastric Pain Syndrome (EPS), can overlap. PDS–EPS overlap tends to reduce patients’ quality of life. Combination therapy with nizatidine and
Yusaku Kajihara
doaj +1 more source